NCT07103447View on ClinicalTrials.gov

Prospective Multicenter Single-arm Trial: AK112 + Nab-paclitaxel/Carboplatin Neoadjuvant for TNBC

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

54

Participants

Timeline

Start Date

September 10, 2025

Primary Completion Date

December 31, 2027

Study Completion Date

December 31, 2028

Conditions
Breast Cancer - Female
Interventions
DRUG

AK112, Carboplatin, Paxlitaxel

The combination of AK112, a platinum-based chemotherapy agent, and Paxlitaxel is administered every three weeks as a neoadjuvant treatment for triple-negative breast cancer. After completing six cycles of this regimen, the participant undergoes surgical treatment.

All Listed Sponsors
lead

Shuangyue Liu

OTHER